A new study points to an unexpected immune connection that could help explain why blood-cell production changes with age: a population of CD4+ T cells with the ability to kill target cells appears to drive the bone marrow toward producing more myeloid cells through the signaling pathway formed by the molecules CCL5 and CCR5. The finding, reported in Nature Aging by Elena Gabandé-Rodríguez, Guillermo Soto-Heredero, Eduardo Carrasco and colleagues, links two processes that are often studied separately—persistent immune activation and age-associated changes in blood formation. It suggests that aging immune cells may not simply reflect changes occurring elsewhere in the body. They may actively instruct the blood-forming system to remodel itself.
The immune system is built around communication. T cells detect signs of infection, abnormal cells or tissue damage, then release molecular signals that recruit and activate other cells. CD4+ T cells are conventionally described as “helper” cells because they coordinate immune responses, while CD8+ T cells are more widely recognized for directly killing infected or malignant cells. But some CD4+ T cells can acquire cytotoxic properties, producing molecules that damage target cells and inflammatory mediators that influence neighboring tissues. The study focuses on these cytotoxic CD4+ T cells and identifies them as drivers of age-associated myelopoiesis—the increased generation of myeloid-lineage blood cells, including monocytes, neutrophils and related innate immune populations.
Myelopoiesis takes place primarily in the bone marrow, where hematopoietic stem and progenitor cells continuously generate the cells needed to replenish blood and immune defenses. Under normal conditions, this production is tightly regulated, balancing the formation of myeloid cells with lymphoid cells such as B and T cells. With advancing age, however, hematopoietic stem cells often become biased toward myeloid output. This phenomenon is sometimes called myeloid skewing. It can provide a rapid supply of innate immune cells, but it may also contribute to chronic inflammation, impaired adaptive immunity and reduced resilience after infection. The new work places cytotoxic CD4+ T cells upstream of this shift, proposing that signals from the aging immune environment can reshape blood production at its source.
The central molecular link is CCL5–CCR5 signaling. CCL5 is a chemokine, a small signaling protein that helps direct immune-cell movement and behavior. CCR5 is its receptor, a molecule on the surface of particular immune and other cells that detects CCL5 and translates the signal into intracellular activity. When CCL5 binds CCR5, it can promote cell migration, activation and communication within inflamed tissues. In the context described by the researchers, cytotoxic CD4+ T cells produce or depend on this signaling axis to influence myeloid development. Rather than acting only as circulating defenders, the T cells appear to participate in a feedback circuit: immune cells release instructions that alter the composition of the future immune-cell supply.
That circuit offers a possible explanation for how relatively persistent immune stimulation can become embedded in the architecture of aging. Cytotoxic CD4+ T cells are known to expand or become more prominent in several settings associated with long-term immune stress, including chronic infections and inflammatory disease. As these cells accumulate or remain activated, their signals could repeatedly reach hematopoietic stem and progenitor cells, either directly or through intermediary cells in the marrow environment. Over time, such exposure could favor progenitors that produce myeloid cells. The resulting increase in innate immune cells might then sustain inflammation, creating a self-reinforcing loop between immune activation and altered blood formation.
The importance of the finding is not that myeloid cells are inherently harmful. Neutrophils and monocytes are essential for containing infections, clearing damaged tissue and initiating repair. The problem arises when production and activation remain elevated without a short-term threat to resolve. Chronic myeloid-biased hematopoiesis can be associated with inflammatory signaling, weaker vaccine responses and a narrower capacity to generate some adaptive immune cells. It may also affect the tissue environment in organs throughout the body. By identifying a T-cell population and a defined chemokine receptor pathway in this process, the study provides a more specific framework for investigating why age-related inflammation persists—and where it might be interrupted.
The work also broadens the picture of immune aging. Researchers have often emphasized senescent cells, changes in stem-cell metabolism, systemic inflammatory molecules and repeated exposure to pathogens as contributors to declining immune function. The new study suggests that the adaptive immune system itself can act as a regulator of hematopoiesis. This is a notable shift in perspective because it treats aging blood production not merely as a consequence of stem-cell wear and tear, but as an outcome shaped by ongoing cellular conversations. Cytotoxic CD4+ T cells may therefore be both products of an aging immune system and active participants in its further remodeling.
The CCL5–CCR5 pathway is already biologically and medically familiar, which could make the finding especially interesting for future research. CCR5 has been investigated in infectious disease, inflammation and cancer, and drugs that interfere with CCR5 signaling have been developed for specific clinical uses. Yet the study does not by itself establish that blocking this pathway would safely reverse age-related myelopoiesis in people. Chemokine networks are highly interconnected, and suppressing one route could affect host defense, tissue repair or the ability to respond to infection. Any therapeutic strategy would need to distinguish harmful chronic signaling from the protective immune responses that use the same molecular machinery.
The findings raise several questions that will determine how broadly the mechanism applies. It will be important to establish how the cytotoxic CD4+ population changes across different human populations, whether its activity predicts particular patterns of blood-cell aging, and how much of the pathway is driven by chronic infection, inflammation or other age-related conditions. Researchers will also need to clarify whether the effect is reversible and whether altering CCL5–CCR5 signaling changes functional outcomes such as immune response, infection susceptibility or inflammatory disease. For now, the study presents a compelling mechanistic link: aging-associated cytotoxic CD4+ T cells can influence the blood-forming system through a chemokine signal, suggesting that the future of immune aging may be shaped by conversations between mature T cells and the stem cells that replenish the blood.
Subject of Research: Cytotoxic CD4+ T cells, age-associated myelopoiesis, and CCL5–CCR5 signaling
Article Title: Cytotoxic CD4+ T cells induce age-associated myelopoiesis through CCL5–CCR5 signaling
Article References: Gabandé-Rodríguez, E., Soto-Heredero, G., Carrasco, E. et al. “Cytotoxic CD4+ T cells induce age-associated myelopoiesis through CCL5–CCR5 signaling.” Nature Aging (2026). https://doi.org/10.1038/s43587-026-01209-9
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s43587-026-01209-9
Keywords: cytotoxic CD4+ T cells, myelopoiesis, immune aging, CCL5, CCR5, hematopoietic stem cells, chronic inflammation, age-associated immunity
